Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isa Mambetsariev

Showing results (51-60 of 78) with videos related to

Pageof 8
Sort By:
Lung Cancer (Amsterdam, Netherlands)|June 20, 2020
Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitorsDan Zhao, Isa Mambetsariev, Haiqing Li, et al.
Medrxiv : the Preprint Server for Health Sciences|September 18, 2025
Cancer Survival at a Comprehensive Cancer Center Compared with Surveillance, Epidemiology, and End Results (SEER) EstimatesRavi Salgia, Joseph Alvarnas, Vijay Trisal, et al.
Cancers|June 2, 2021
Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint InhibitorsDan Zhao, Haiqing Li, Isa Mambetsariev, et al.
Journal of Clinical Medicine|November 26, 2022
Pyramidal Decision Support Framework Leverages Subspecialty Expertise across Enterprise to Achieve Superior Cancer Outcomes and Personalized, Precision Care PlansLinda D Bosserman, Isa Mambetsariev, Colton Ladbury, et al.
Translational Lung Cancer Research|June 15, 2026
Case report: durable response to osimertinib, radiotherapy, and chemotherapy combination in advanced non-small cell lung cancer with atypical metastasisJavier Arias-Romero, Isa Mambetsariev, Jeremy Fricke, et al.
International Journal of Oncology|April 3, 2020
Effects of selected deubiquitinating enzyme inhibitors on the proliferation and motility of lung cancer and mesothelioma cell linesTamara Mirzapoiazova, Alexander Pozhitkov, Arin Nam, et al.
Iscience|November 16, 2020
Activation of EPHA2-ROBO1 Heterodimer by SLIT2 Attenuates Non-canonical Signaling and Proliferation in Squamous Cell CarcinomasSaumya Srivastava, Ka Ming Pang, Mari Iida, et al.
Frontiers in Oncology|March 2, 2023
Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapyMichael R Sayer, Isa Mambetsariev, Kun-Han Lu, et al.
Translational Lung Cancer Research|June 15, 2026
Patterns of central nervous system disease and molecular landscape in epidermal growth factor receptor exon 20 insertion mutated non-small cell carcinomaAmanda Reyes, Isa Mambetsariev, Jeremy Fricke, et al.
Journal of Clinical Medicine|June 21, 2020
Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting-Role of Academic and Hybrid ModelingRavi Salgia, Isa Mambetsariev, Tingting Tan, et al.
Pageof 8

Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
Lung Cancer (Amsterdam, Netherlands)|June 20, 2020
Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitorsDan Zhao, Isa Mambetsariev, Haiqing Li, et al.
Medrxiv : the Preprint Server for Health Sciences|September 18, 2025
Cancer Survival at a Comprehensive Cancer Center Compared with Surveillance, Epidemiology, and End Results (SEER) EstimatesRavi Salgia, Joseph Alvarnas, Vijay Trisal, et al.
Cancers|June 2, 2021
Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint InhibitorsDan Zhao, Haiqing Li, Isa Mambetsariev, et al.
Journal of Clinical Medicine|November 26, 2022
Pyramidal Decision Support Framework Leverages Subspecialty Expertise across Enterprise to Achieve Superior Cancer Outcomes and Personalized, Precision Care PlansLinda D Bosserman, Isa Mambetsariev, Colton Ladbury, et al.
Translational Lung Cancer Research|June 15, 2026
Case report: durable response to osimertinib, radiotherapy, and chemotherapy combination in advanced non-small cell lung cancer with atypical metastasisJavier Arias-Romero, Isa Mambetsariev, Jeremy Fricke, et al.
International Journal of Oncology|April 3, 2020
Effects of selected deubiquitinating enzyme inhibitors on the proliferation and motility of lung cancer and mesothelioma cell linesTamara Mirzapoiazova, Alexander Pozhitkov, Arin Nam, et al.
Iscience|November 16, 2020
Activation of EPHA2-ROBO1 Heterodimer by SLIT2 Attenuates Non-canonical Signaling and Proliferation in Squamous Cell CarcinomasSaumya Srivastava, Ka Ming Pang, Mari Iida, et al.
Frontiers in Oncology|March 2, 2023
Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapyMichael R Sayer, Isa Mambetsariev, Kun-Han Lu, et al.
Translational Lung Cancer Research|June 15, 2026
Patterns of central nervous system disease and molecular landscape in epidermal growth factor receptor exon 20 insertion mutated non-small cell carcinomaAmanda Reyes, Isa Mambetsariev, Jeremy Fricke, et al.
Journal of Clinical Medicine|June 21, 2020
Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting-Role of Academic and Hybrid ModelingRavi Salgia, Isa Mambetsariev, Tingting Tan, et al.
Pageof 8